Actively Recruiting

All Genders
NCT07353463

Shanghai Clinical Cohort - Parkinson's Disease (Reserve)

Led by Ruijin Hospital · Updated on 2026-03-05

700

Participants Needed

1

Research Sites

91 weeks

Total Duration

On this page

Sponsors

R

Ruijin Hospital

Lead Sponsor

H

Huashan Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this observational cohort studyis to establish a high-quality clinical cohort of Parkinson's disease (PD) and multiple system atrophy (MSA) patients in Shanghai, in order to improve early diagnosis, precise subtyping, disease monitoring, and to provide a resource for translational research and novel therapy development. The main questions it aims to answer are: * Can multimodal data (clinical, imaging, electrophysiology, biospecimens, and genetics) help identify early biomarkers for PD and MSA? * Can precise subtyping and long-term monitoring predict disease progression and therapeutic response? Researchers will compare 600 PD patients and 100 MSA patients to evaluate differences in clinical features, biomarkers, imaging, and prognosis. Participants will: * Provide informed consent and complete baseline demographic and medical history collection. * Undergo standardized clinical evaluations, including motor and non-motor symptom scales, cognitive and quality-of-life assessments. * Provide biological samples (blood, saliva, optional CSF). * Receive brain imaging (MRI, optional PET/SPECT) and electrophysiological recordings (EEG, fNIRS). * Participate in longitudinal follow-up visits every 6 months for repeat assessments. This study will create a sustainable, multicenter, and sharable cohort platform to support early identification, personalized intervention, and therapeutic development for neurodegenerative diseases

CONDITIONS

Official Title

Shanghai Clinical Cohort - Parkinson's Disease (Reserve)

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Clinical diagnosis of Parkinson's disease according to Chinese Diagnostic Criteria (2016) or clinically probable multiple system atrophy according to Chinese Expert Consensus (2022)
  • Willingness to provide biospecimens including optional cerebrospinal fluid, blood, and saliva
  • Agreement to complete neuroimaging exams (MRI, PET/SPECT) and disease-specific clinical assessments
  • Provision of written informed consent
Not Eligible

You will not qualify if you...

  • Unclear or uncertain diagnosis
  • History of stroke, head trauma, hydrocephalus, brain tumor, intracranial hypertension, or intracranial surgery
  • Evidence of intracranial organic lesions on CT or MRI
  • Severe anxiety, depression, or schizophrenia
  • Severe comorbidities affecting heart, lungs, liver, kidneys, endocrine, or blood systems
  • Aphasia, severe dysarthria, or other conditions impairing clinical assessments
  • Expected poor compliance

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Department of neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, China, 200025

Actively Recruiting

Loading map...

Research Team

J

Jun Liu, Professor

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here